Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Natera, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Natera, Inc.

Regulatory records
1
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 1 FDA record to the applicant name Natera, Inc.. It includes 1 original PMA approval. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from May 15, 2026 to May 15, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code PQP appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P260004, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 13011a Mccallen Pass, Austin, TX, 78753. Recorded on P260004, decision dated May 15, 2026.

Changes described in PMA records

P260004: Signatera CDx

FDA’s recorded scope: SignateraTM CDx is a personalized, tumor-informed, multiplex-PCR and next-generation sequencing (NGS)based assay that detects circulating tumor DNA (ctDNA) molecular residual disease (MRD) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs), using bespoke assays designed to track somatic variants identified from sequencing of a patients formalin-fixed, paraffin-embedded (FFPE) tumor specimen.SignateraTM CDx is intended to identify patients with ctDNA MRD positive status who may benefit from treatment listed in Table 1, in accordance with the approved therapeutic product labeling.Table 1: SignateraTM CDx Indicated Use and Associated TherapyBiomarker Indication TherapyctDNA MRD Muscle Invasive Bladder Cancer (MIBC) TECENTRIQ (atezolizumab), TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs)

May 15, 2026

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

  1. Signatera CDx

    P260004 · PMA decision
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.